Becker · Health care law monthly 2004 · legal analysis and narrative commentary · n=?

Ambulatory surgery centers--current legal issues 2004 (Part 2).

Cited 1 times in the scientific literature.

Level 5 - mechanism / opinion, no new human data

Level 5 by design analogy (expert legal analysis and commentary, not clinical CEBM)

PubMed 15188633 · record verified 2026-08-29

What was done

The author analyzed regulatory requirements, safe harbor provisions, the anti-kickback statute, tax rules, and relevant court decisions affecting ambulatory surgery centers (ASCs) as of 2004. The analysis focused on compliance considerations regarding physician-owner redemption, share valuation, deductible and co-payment waivers, third-party equipment leasing, non-covered procedure facility fee structures, tax-exempt joint venture status, and antitrust price-fixing risks.

What was found

The abstract reports qualitative legal analysis and regulatory recommendations; no numerical or statistical data are reported. Key findings indicate that share sales at below fair market value risk violation of anti-kickback statutes; co-payments and deductibles for Medicare and Medicaid patients should not be discounted without documented financial hardship; third-party equipment leasing models can threaten state licensure and Medicare certification; procedures lacking ASC facility charges require fair market value fees to avoid unlawful referral inducements; tax-exempt joint venture partners must maintain operational control; and hospital-ASC joint ventures must separate pricing negotiations to mitigate antitrust price-fixing liability.

Why it matters

This article outlines practical compliance strategies for ASC operators, healthcare attorneys, and investors to structure business transactions and ownership models in accordance with federal healthcare regulations and antitrust laws.

Limits

This is a narrative legal review and expert commentary rather than an empirical or clinical study. The abstract provides no quantitative data, sample size, or systematic review methodology, and the regulatory guidance is specific to United States law as of 2004.

Cited by